Authors
FADRUS, Pavel (203 Czech Republic, belonging to the institution); Václav VYBÍHAL (203 Czech Republic, belonging to the institution); Ivana ROŠKOVÁ (703 Slovakia, belonging to the institution); Iveta SELINGEROVÁ (203 Czech Republic); Martin SMRČKA (203 Czech Republic, belonging to the institution); Radim JANČÁLEK (203 Czech Republic, belonging to the institution); Jiří ŠÁNA (203 Czech Republic, belonging to the institution); Ondřej SLABÝ (203 Czech Republic, belonging to the institution); Petr POSPÍŠIL (203 Czech Republic, belonging to the institution); Ludmila HYNKOVÁ (203 Czech Republic, belonging to the institution); Jan GARCIC (203 Czech Republic); Renata BELANOVÁ (203 Czech Republic); Jan KRISTEK (203 Czech Republic); Andrea ŠPRLÁKOVÁ-PUKOVÁ (203 Czech Republic, belonging to the institution); Zdeněk MACKERLE (203 Czech Republic, belonging to the institution); Vilém JURÁŇ (203 Czech Republic, belonging to the institution); Marek SOVA (203 Czech Republic, belonging to the institution); Eduard NEUMAN (203 Czech Republic, belonging to the institution); Hana VALEKOVÁ (703 Slovakia, belonging to the institution); Radek LAKOMÝ (203 Czech Republic, belonging to the institution); Miloš HOLÁNEK (203 Czech Republic, belonging to the institution); Roman HRSTKA (203 Czech Republic); Michaela ŠVAJDOVÁ (703 Slovakia, belonging to the institution); Kateřina POLÁCHOVÁ (203 Czech Republic, belonging to the institution); Ivana KOLOUŠKOVÁ (203 Czech Republic, belonging to the institution); Pavel ŠLAMPA (203 Czech Republic, belonging to the institution) and Tomáš KAZDA (203 Czech Republic, belonging to the institution)
Edition
Reports of Practical Oncology and Radiotherapy, GDANSK, VIA MEDICA, 2024, 1507-1367
Links
LX22NPO5102, research and development project. NU22-03-00159, research and development project. NV18-03-00469, research and development project. BBMRI.cz IV, large research infrastructures. CZECRIN IV, large research infrastructures.
V originále
lt; 0.001; hazard ratio (HR) 0.47, p = 0.004] with median follow-up of 58 months. Cumulative incidence for local, distant, and extracranial control was not significantly different between groups, with 12-month cumulative control of 22% vs. 18%, 44% vs. 29%, and 35% vs. 32% for stereotactic and WBRT group, respectively. WBRT was an independent factor for better distal brain control. Conclusions: Real world data demonstrating significantly better overall survival in patients treated with postoperative targeted radiotherapy compared with postoperative WBRT is presented, with no significant difference in cumulative incidence for local or distant brain control. The majority of patients with targeted radiotherapy had a fractionated dose schedule with outcomes comparable to single-dose radiation trials of postoperative targeted radiotherapy.